ANTI-B-CELL THERAPY AT IMMUNE INFLAMMATORY RHEUMATIC DISEASES: EFFICACY AND TOLERABILITY IN 229 PATIENTS

ANTI-B-CELL THERAPY AT IMMUNE INFLAMMATORY RHEUMATIC DISEASES: EFFICACY AND TOLERABILITY IN 229 PATIENTS

Objective: to assess the efficacy and tolerability of Rituximab treatment in patients with serious immune inflammatory rheumatic diseases (IRD) like systemic lupus erythematosus (SLE), systemic sclerosis (SS), systemic vasculitis (SV), Sjogren syndrome (SjS), dermatomyositis/polymyositis (DM/PM).Sub...

Full description

Bibliographic Details
Main Authors: L. P. Ananieva, S. K. Soloviyov, T. V. Beketova, V. I. Vasiliev, O. A. Antelava, E. N. Aleksandrova, O. A. Koneva, M. E. Tsanyan, O. V. Desinova, O. A. Logvinenko, A. V. Volkov, A. N. Helkovskaya-Sergeeva, A. A. Novikov, A. A. Aleksankin, Ye. L. Nasonov
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2014-10-01
Series:Научно-практическая ревматология
Subjects:
immune inflammatory (autoimmune) rheumatic diseases
rituximab
b-cells
Online Access:https://rsp.mediar-press.net/rsp/article/view/1982

Internet

https://rsp.mediar-press.net/rsp/article/view/1982

Similar Items